硝子体手術器具の世界市場 2024年～2031年

概要

硝子体手術器具の世界市場は、2023年に12億1,620万米ドルに達し、2031年には21億2,130万米ドルに達すると予測され、予測期間2024-2031年のCAGRは7.2%です。

硝子体手術器具は、硝子体手術と呼ばれる外科手術の際に、眼球の中心部を満たしている透明なゲル状の物質である硝子体を患者の眼球から除去するために眼科で使用される医療器具です。硝子体手術は、網膜剥離、糖尿病網膜症、網膜上膜、黄斑円孔など、さまざまな眼疾患の治療のために行われます。

硝子体は、体内で再び硝子体が生成されるようになるまで、透明な液体または気泡で置換されます。市場は、糖尿病性網膜症や網膜剥離の有病率の増加、硝子体手術手技の技術進歩、眼科手術手技の増加といった要因によって牽引されます。

市場力学：

促進要因

糖尿病性網膜症および網膜剥離の有病率の増加

世界の硝子体手術装置市場の需要は、複数の要因によって牽引されています。主な要因の1つは、糖尿病性網膜症および網膜剥離の有病率の増加が、硝子体手術装置市場を牽引すると予想されることです。

糖尿病性網膜症は、働き盛りの成人における視力低下の主な原因であり、世界の糖尿病有病率の増加によりその発生率は上昇しています。2024年2月に出版されたJournal of Ayurveda and Integrated Medical Scienceによると、糖尿病網膜症（DR）は糖尿病の微小血管合併症の中で最も頻度が高いです。糖尿病患者の糖尿病性網膜症の有病率は世界全体で27.0％と推定され、世界で40万人が失明しています。糖尿病網膜症は網膜の血管に影響を及ぼします。一般的に両眼に発症し、放置すると視力低下につながります。

2022年1月のNCBI調査によると、様々な病院ベースの調査のプール分析に基づき、DRの有病率はアフリカで31.6％、エチオピアで19.48％と報告されています。世界保健機関（WHO）によると、世界では3,700万人が網膜剥離で失明していると推定されています。

網膜剥離（RD）は、永久的な視力喪失につながる可能性のある重篤な眼疾患であり、硝子体手術装置の需要にも寄与しています。裂孔原性網膜剥離（RRD）は視力を脅かす疾患で、米国では人口10万人あたり年間10～18人が発症していると推定されています。網膜裂孔は急性症候性PVD患者の8％～16％で確認され、未治療の場合、患者の30％～50％でRRDに進行する可能性があります。

制約

硝子体手術装置の高価格、治療に伴う患者の不快感やリスク、熟練した医療従事者の不足、厳しい規制要件などの治療要因が、市場の妨げになると予想されます。

このレポートの詳細情報- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病網膜症および網膜剥離の有病率の増加
    • 硝子体手術の技術的進歩
  • 抑制要因
    • 硝子体手術器具の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• 硝子体手術器械
• 硝子体手術用パック
• 光凝固レーザー
• 照明装置
• その他

第7章 用途別

• 糖尿病網膜症
• 網膜剥離
• 黄斑円孔
• 硝子体出血
• その他

第8章 エンドユーザー別

• 病院
• 眼科クリニック
• 外来手術センター

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Alcon
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bausch Health Companies Inc.
• BVI
• DORC Holding B.V
• Johnson & Johnson
• NIDEK CO. LTD
• Blink Medical
• Topcon Corporation
• Carl Zeiss Meditec AG
• Hoya Surgical Optics

第12章 付録

Overview

The global vitrectomy devices market reached US$ 1216.2 million in 2023 and is expected to reach US$ 2121.3 million by 2031 growing with a CAGR of 7.2% during the forecast period 2024-2031.

Vitrectomy devices are medical instruments used in ophthalmology to remove the vitreous humor, a clear gel-like substance that fills the center of the eye, from a patient's eye during a surgical procedure called vitrectomy. Vitrectomy is performed to treat various eye conditions such as retinal detachments, diabetic retinopathy, epiretinal membranes, and macular holes.

The vitreous is replaced with a clear fluid or a gas bubble until the body begins producing the vitreous again. The market is driven by factors such as the increasing prevalence of diabetic retinopathy and retinal detachment, technological advancement in vitrectomy surgical procedures and the rising number of eye surgical procedures would drive this market growth.

Market Dynamics: Drivers

Increasing prevalence of diabetic retinopathy and retinal detachment

The demand for the global vitrectomy devices market is driven by multiple factors. One of the key factors is the increasing prevalence of diabetic retinopathy and retinal detachment is expected to drive the vitrectomy devices market.

Diabetic retinopathy is a leading cause of vision loss among working-age adults, and its incidence is rising due to the growing prevalence of diabetes globally. According to the Journal of Ayurveda and Integrated Medical Science publication in February 2024, Diabetic retinopathy (DR) is the most frequent microvascular complication of Diabetes mellitus. Globally the prevalence of Diabetic retinopathy among diabetic patients is estimated to be 27.0% which leads to 0.4 million blindness in the world. It affects blood vessels in the retina. It commonly affects both eyes and can lead to vision loss if left untreated.

As per NCBI research studies in January 2022, based on a pooled analysis of various hospital-based studies the prevalence of DR is reported to be 31.6% in Africa and 19.48%in Ethiopia. According to the World Health Organization (WHO), it is estimated that DR makes up 37 million cases of blindness in the world.

Retinal detachments (RDs) constitute a severe ocular condition that can lead to permanent vision loss is also contribute to the demand for vitrectomy devices. Rhegmatogenous retinal detachment (RRD) is a vision-threatening condition with an estimated incidence of 10 to 18 per 100,000 population per year in the United States. Retinal breaks are identified in 8% to 16% of patients with acute symptomatic PVD and may progress to RRD in 30% to 50% of patients if untreated.

Restraints

Factors such as the high cost of vitrectomy devices, patient discomfort & risk associated with the treatment, lack of skilled healthcare professionals, and stringent regulatory requirements, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global vitrectomy devices are segmented based on product type, application, end-users, and region.

The vitrectomy machines segment accounted for approximately 49.6% of the global vitrectomy devices market share

The vitrectomy machines segment is expected to hold the largest market share over the forecast period. Vitrectomy machines are the key equipment used in vitrectomy procedures, which involve the removal of the vitreous humor from the eye to treat various conditions. These machines are designed to precisely control the removal of the vitreous and provide surgeons with improved visibility and control during the operation.

Vitrectomy machines such as Alcon Constellation, DORC EVA Bausch + Lomb Stellaris PC, Associate 6000 Dual, Associate 2500 Compact System, and Syntec VitMan Vitrectomy System are some of the vitrectomy devices and systems used for treating the conditions such as retinal detachments, vitreous hemorrhage, endophthalmitis, and macular holes. The development of new generation machines with advanced features such as improvised fluidics, high cut rates, small gauge size, and intraocular pressure control helps to drive this segment's growth.

Moreover, key players strategies such as partnerships & collaborations, technological advancements in the devices, and major players' innovative launches would propel this segment's growth in the market. For instance, in January 2022, DORC International and WEFIS GmbH are excited to announce a strategic partnership, based on an equity investment by DORC. The partnership will focus on research and development to deliver innovation in the performance, efficiency, and usability of instruments for cataract surgery.

Also, in March 2022, DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in the retina, cataract, and combined surgery. Surgeons have used Eva Nexus in more than 1,500 surgical procedures during the limited-release phase.

Similarly, in August 2022, Vortex Surgical launched the TID Pharos Illuminated Depressor the first standalone transilluminator that can be used across all existing vitrectomy machine platforms without requiring a skilled assistant. The product is the second generation of the company's line of transillumination products, which includes the first-generation Todorich Illuminated Depressor.

Geographical Analysis

North America accounted for approximately 43.2% of the global vitrectomy devices market share

North America region is expected to hold the largest market share over the forecast period. Owing to the growing prevalence of ophthalmic disorders such as diabetic retinopathy, macular hole, and retinal detachment, & well advanced healthcare infrastructure, is expected to contribute towards the growth of the market in the region.

Moreover, major key players' presence, financial investments, product launches, and approvals would drive this market growth in this region. For instance, in August 2022, Iantrek Inc. announced the closing of a $23M Series B financing. The oversubscribed financing was led by institutional investors Visionary Ventures and Sectoral Asset Management, Inc. According to the company, the capital will be used to initiate clinical introduction and post-marketing studies of Iantrek's micro-interventional glaucoma surgical (MIGS) devices in the United States.

Also, in April 2023, Nova Eye Medical Limited announced that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its iTrack Advance, a new canaloplasty device.

Similarly, in June 2024, Alcon announced that UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon's highly anticipated Unity portfolio.

Market Segmentation

By Product Type

• Vitrectomy Machines
• Vitrectomy packs
• Photocoagulation lasers
• Illumination devices
• Others

By Application

• Diabetic Retinopathy
• Retinal Detachment
• Macular Hole
• Vitreous Hemorrhage
• Others

By End-users

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the vitrectomy devices market include Alcon, Bausch Health Companies Inc., BVI, DORC Holding B.V., Johnson & Johnson, NIDEK CO., LTD., Blink Medical, Topcon Corporation, Carl Zeiss Meditec AG, Hoya Surgical Optics

Key Developments

• In April 2024, Carl Zeiss Meditec AG announced that, after securing all required regulatory approvals, it has completed the acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements ZEISS Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataracts, glaucoma, and refractive errors.
• In June 2023, ZEISS introduced revolutionary VISUMAX 800 and Quatera 700 medical devices in Bangladesh. VISUMAX 800 enables surgeons to perform corneal refractive surgeries, such as LASIK and SMILE, with unparalleled accuracy, speed, and reliability. This innovative device offers superior patient comfort, faster recovery times, and exceptional visual outcomes, reinforcing ZEISS's commitment to advancing eye care solutions in Bangladesh.

Why Purchase the Report?

• To visualize the global vitrectomy devices market segmentation based on product type, application, end-users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of vitrectomy devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global vitrectomy devices market report would provide approximately 62 tables, 59 figures, and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-users
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Diabetic Retinopathy and Retinal Detachment
    • 4.1.1.2. Technological Advancement in Vitrectomy Surgical Procedures
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Vitrectomy Devices
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Vitrectomy Machines *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Vitrectomy packs
• 6.4. Photocoagulation lasers
• 6.5. Illumination devices
• 6.6. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
• 7.2. Diabetic Retinopathy *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Retinal Detachment
• 7.4. Macular Hole
• 7.5. Vitreous Hemorrhage
• 7.6. Others

8. By End-users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 8.1.2. Market Attractiveness Index, By End-users
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ophthalmology Clinics
• 8.4. Ambulatory Surgical Centers

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Alcon *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bausch Health Companies Inc.
• 11.3. BVI
• 11.4. DORC Holding B.V
• 11.5. Johnson & Johnson
• 11.6. NIDEK CO. LTD
• 11.7. Blink Medical
• 11.8. Topcon Corporation
• 11.9. Carl Zeiss Meditec AG
• 11.10. Hoya Surgical Optics

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us